INTRODUCTION
NARCOLEPSY IS A DISORDER CHARACTERIZED BY EX-CESSIVE DAYTIME SLEEPINESS, CATAPLEXY, AND UN-USUAL RAPID TRANSITIONS FROM THE AWAKE state to rapid eye movement (REM) sleep. In the first edition of the International Classification of Sleep Disorders (ICSD), 1 the diagnosis of narcolepsy had dual essential criteria: (1) narcolepsy with cataplexy, defined as hypersomnia that persists more than 3 months plus episodes of cataplexy, and (2) narcolepsy without cataplexy, defined as hypersomnia manifested as shortened sleep latency with narcolepsy-related symptoms, such as sleep paralysis, hypnagogic hallucination or sleep disruption, plus a sleep-onset REM period (SOREMP) on nocturnal polysomnography (PSG) or 2 or more SOREMPs on the multiple sleep latency test (MSLT) examination. 1 Recently, the ICSD was revised to its second edition (ICSD-2) in which narcolepsy with cataplexy and narcolepsy without cataplexy are separetely defined. 2 The diagnosis of narcolepsy with cataplexy is easy when patients show typical cataplexy.
However, the diagnosis of narcolepsy without cataplexy must be made with PSG followed by an MSLT, and it can be diagnosed only when 2 or more SOREMPs on the MSLT are observed. 2 Hypocretin/orexin is a hypothalamic neuropeptide involved in sleep-wake regulation and energy homeostasis. 3, 4 It has recently been shown that hypocretin deficiency is closely related to the pathogenesis of human narcolepsy and that the hypocretin-1/ orexin-A level in cerebrospinal fluid (CSF) is markedly decreased in most patients with narcolepsy with cataplexy. [5] [6] [7] However, studies on narcolepsy without cataplexy have been carried out in only a small number of patients, and the results have been controversial. [6] [7] [8] [9] [10] [11] [12] With regard to HLA typing, DR2, DRB1*1501 (a subtype of DR2), and DQB1*0602 (a subtype of DQ1) have been shown to be strongly associated with narcolepsy with cataplexy. [13] [14] [15] In contrast, narcolepsy without cataplexy is less associated with HLA types than is narcolepsy with cataplexy. 16 These previous results on CSF hypocretin-1 levels and HLA suggest that narcolepsy without cataplexy might be a heterogeneous clinical syndrome, whereas narcolepsy with cataplexy forms a uniform entity. However, systematic investigation regarding CSF hypocretin-1 and its relationship to both clinical parameters and HLA types among patients having narcolepsy without cataplexy has been limited.
The aim of the present study was thus to examine the CSF hypocretin-1 levels in patients who had narcolepsy without cataplexy and to clarify the CSF hypocretin-1 level correlation with clinical characteristics and findings on the MSLT as well as HLA types.
METHODS
Seventeen patients who had narcolepsy without cataplexy (5 male, 12 female) were included in the study. Our series included 5 patients whose CSF hypocretin-1 levels were reported by Kanbayashi and colleagues. 6 However, those investigators were focusing mainly on the difference between narcolepsy and idiopathic hypersomnia. Thus, the purpose of that report was entirely different from that of the present study.
In this study, the ICSD-1 was used for the diagnosis of narcolepsy. The diagnosis of narcolepsy without cataplexy was made according to the second essential criterion of narcolepsy, which is used for patients not presenting with cataplexy, in the ICSD-1 as follows 1 : (1) excessive daytime sleepiness, (2) REM-related symptoms such as hypnagogic hallucinations and sleep paralysis, and (3) sleep latency of less than 10 minutes plus 1 or more SOREMPs on PSG or a mean sleep latency of less than 5 minutes plus 2 or more SOREMPs out of 4 or 5 sessions on the MSLT. Except for 1 patient who showed a typical SOREMP on PSG and only 1 SOREMP on the MSLT, all of the other patients fulfilled the ICSD-2 criteria of narcolepsy without cataplexy, ie, a mean sleep latency of less than 8 minutes and 2 or more SOREMPs. 2 Cataplexy was defined as the sudden loss of bilateral muscle tone provoked by strong emotion, 1,2 and its absence was confirmed based on clinical interview by board-certified sleep specialists. Because mild hypotonus may be overlooked not only by examiners, but also by patients themselves, possible cataplexy episodes, including even mild sensations of weakness, were carefully evaluated and excluded. Patients were also confirmed to have no other sleep disorders, such as obstructive sleep apnea syndrome, restless legs syndrome, or periodic limb movement disorder, which could cause excessive daytime sleepiness.
Physical and neurologic examinations were normal in all patients. A family history of narcolepsy was not noted in any of the patients. None of the patients was medicated with either central nervous system stimulants or tricyclic antidepressants when enrolled. Clinical profiles such as age, age at clinical onset, duration of illness, and usual length of nocturnal sleep time at the time of evaluation are shown in Tables 1 and 2 . HLA markers for narcolepsy were also examined. HLA DR2 was screened in all patients, and a detailed HLA analysis of DQB1*0602 was made in 5 patients.
PSG, including 4 channels of scalp electroencephalogram (C 3 , C 4 , O 1 , O 2 ), electrooculogram, chin electromyogram, electrocardiogram, nasal/oral airflow, chest/abdominal respiratory effort, snoring, and anterior tibialis electromyogram, were recorded for all patients. After confirming that the nocturnal PSG fulfilled the conditions of at least 7 hours of nocturnal sleep and a sleep efficiency of 80% or more, we conducted the MSLT using a standard protocol in all patients. 17 Sleep stages were scored according to the standard criteria. 18 Sleep onset on the MSLT was defined as either the appearance of 3 consecutive 30-second epochs of stage 1 or an epoch of any other sleep stages including REM sleep. A SOREMP was defined as the appearance of an epoch of REM sleep either during the first 20 minutes on nocturnal PSG or during the first 15 minutes of the MSLT. Regarding the MSLT variables, sleep propensity (manifested as mean sleep latency) and REM propensity (estimated as both the percentage of naps with SOREMPs and the mean REM latency) in 4 or 5 sessions of the MSLT were analyzed. Subjective excessive daytime sleepiness was scored by the Epworth Sleepiness Scale. 19 CSF was examined after written informed consent was obtained. The CSF was kept frozen (-80º C) prior to the hypocretin-1 measurement. CSF hypocretin-1 levels were measured by a commercially available radioimmunoassay kit (Phoenix Pharmaceuticals, Belmont, Calif). Considering that a CSF hypocretin-1 level below 110 pg/mL is diagnostic for narcolepsy with cataplexy, 7 our patients were divided into low (< 110 pg/mL) and normal (> 110 pg/mL) groups. Although a CSF hypocretin-1 level of more than 200 pg/mL is considered a normal value, 7 we included 1 patient with mildly decreased hypocretin-1 levels (110-200 pg/ mL) in the normal group to compare the clinical characteristics between the 2 groups. Those parameters described above were compared between the 2 groups. Statistical analysis was carried out using the χ 2 test and the Mann-Whitney test with StatView (version 5) software. A p value of less than .05 was considered significant.
RESULTS
Demographics, characteristics of narcoleptic symptoms, and MSLT findings on each patient are shown in Table 1 . CSF hypocretin-1 levels were undetectably low (< 40 pg/mL) in 3 patients and markedly decreased in 2 patients (51, 53 pg/mL). These 5 patients comprised the low group. Eleven patients who had CSF hypocretin-1 levels of more than 200 pg/mL and a patient with a level of 187 pg/mL (patient 6) comprised the normal group.
7 The CSF hypocretin-1 level in the normal group ranged from 187 to 475 pg/mL, with a mean of 287.6 ± 75.4 pg/mL.
Comparison of clinical parameters and MSLT results between the 2 groups is shown in Table 2 . Age at onset of hypersomnia ranged from 6 to 15 years (mean 11.8 ± 3.4 years) in the low group, whereas the normal group developed hypersomnia at ages of 15 to 23 years (mean 17.6 ± 2.4 years); the age of onset was significantly younger in the low group. Duration of disease ranged from 3 to 35 years in the low group and from 0.5 to 26 years in the normal group, and the values were not significantly different between the 2 groups. One patient in the low group and 3 in the normal group had a disease duration of 3 years or less. Mean usual length of night sleep time ranged from 5.5 to 8.0 hours in the low group and from 6.0 to 9.5 hours in the normal group, showing no statistical difference between the 2 groups. The Epworth Sleepiness Scale score was more than 11 points in all patients and did not differ between the 2 groups.
Mean sleep latency on the MSLT examination ranged from 0.9 to 3.4 minutes in the low group and from 0.1 to 5.0 minutes in the normal group, showing no statistical difference between the 2 groups. The number of SOREMPs out of 4 or 5 MSLT sessions ranged from 1 to 4 in the low group and from 2 to 4 in the normal group. The patient with only 1 SOREMP on the MSLT showed a sleep latency of 3.5 minutes and a REM latency of 4 minutes on PSG carried out before the MSLT. The percentage of naps with SOREMPs on MSLT did not show any statistical difference between the 2 groups. However, mean REM latency ranged from 2.0 to 5.2 minutes (mean 3.3 ± 1.3 minutes) in the low group and from 2.0 to 12.4 minutes (mean 7.5 ± 3.3 minutes) in the normal group, showing that the REM latency was significantly shorter in the low group. HLA-DR2 was positive in 9 patients. The CSF hypocretin-1 levels and their association with positive and negative results of HLA-DR2 are shown in the Figure. All of the patients in the low group were DR2 positive, whereas DR2 was positive in only 33.3% (4 cases) in the normal group. However, comparison of clinical parameters and MSLT results between the patients divided by positive or negative HLA-DR2 showed no statistical difference. Detailed HLA analysis was carried out for 5 patients in the normal group. Only 1 was DQB1*0602 positive; thus, at least 10 out of 12 patients (83.3%) with normal CSF hypocretin-1 levels were determined to be HLA-DQB1*0602 negative.
DISCUSSION
In this study, we investigated the CSF hypocretin-1 levels in patients with well-characterized narcolepsy without cataplexy. Previous reports on the relationship between HLA profile and CSF hypocretin-1 levels in both narcolepsy with and without cataplexy are summarized in Table 3 . Except for the report by Ebrahim et al showing that CSF hypocretin-1 level was markedly decreased in all the narcoleptic patients without cataplexy but not as deficient as in patients with narcolepsy with cataplexy, 8 decreased CSF hypocretin-1 levels were seen in fewer than 15% of the patients of narcolepsy without cataplexy. 6, 7, [9] [10] [11] [12] In the present study, levels of CSF hypocretin-1 were markedly decreased in approximately one third of the patients who had narcolepsy without cataplexy, and the rate was higher than expected.
Considering that our patients were generally young, it is possible that patients with narcolepsy with cataplexy in the early stages of disease prior to the development of cataplexy may have been included in our patient population, leading to the higher rate of the patients with low CSF hypocretin-1. Generally, cataplexy develops within several months after the onset of hypersomnia in most patients with narcolepsy. 20 In the present study, the clinical states and CSF hypocretin-1 levels were examined at least 3 years after the onset of hypersomnia in all of the patients with de- Subtypes of Narcolepsy Without Cataplexy-Oka et al creased CSF hypocretin-1, whereas the examination was carried out within 3 years after the onset of excessive daytime sleepiness in 3 patients out of 12 in the normal group. Especially in the low group, the onset of hypersomnia was more than 10 years before the present evaluation in 3 patients, and 1 of them developed hypersomnia 35 years before. Therefore, it is rather unlikely that they would develop cataplexy in the future. As another option, we should consider the possibility that mild cataplexy might have been overlooked. However, since all of the clinical interviews and examinations were made carefully by board-certified sleep specialists in our study, this possibility is also unlikely. Therefore, our patients were judged as having true narcolepsy without cataplexy, and we would like to emphasize that a certain number of narcoleptic patients without cataplexy show markedly decreased CSF hypocretin-1 levels. Because hypocretin-1 deficiency has been commonly recognized in patients with narcolepsy with cataplexy, a strong association between the mechanism of cataplexy and hypocretin-1 deficiency has been assumed. 5, 6 However, the present results indicate that lowered CSF hypocretin-1 levels could also be recognized in patients with narcolepsy without cataplexy. This finding is compatible with the report in which patients with secondary hypersomnia due to a neurologic disorder showed both SOREMPs on the MSLT and decreased CSF hypocretin-1 level but did not develop cataplexy throughout the clinical course. 21 Among the clinical variables, the MSLT in the low group showed a shorter REM latency than in the normal group, whereas percentage of naps with SOREMPs and severity of excessive daytime sleepiness, as manifested on both mean sleep latency on the MSLT and the Epworth Sleepiness Scale, did not show any difference between the 2 groups. This finding indicates that REM propensity is partially increased in the low group, leading to the speculation that the degree of REM pathology is somewhat stronger in the low group compared with the normal group. In addition, the onset of excessive daytime sleepiness was earlier in the low group than in the normal group. Although the reason for this phenomenon is unknown, the result seems to be in line with that of an earlier report in which narcolepsy symptoms were more severe in patients with early-onset than those with late-onset disease. 20 One of the most striking findings in our study was that HLA-DR2 was positive in all of the patients in the low group, whereas all of the patients with negative HLA-DR2 had normal CSF hypocretin-1 values. As indicated in Table 3 , among the previously reported patients with narcolepsy with cataplexy, the CSF Percentage of patients with positive DQB1*0602. hypocretin-1 level was low in most of the patients with HLA-DQB1*0602 [8] [9] [10] [11] [12] or DR2. 6 On the other hand, the CSF hypocretin-1 level was mostly normal in those who were HLA-DQB1*0602 7,9-11 or DR2 negative. 6 These results corroborate the idea that there could exist a strong relationship between HLA profile and CSF hypocretin-1 level in narcolepsy with cataplexy. 9 Young and colleagues reported that HLA DQB1*0602 positivity in patients with narcolepsy without cataplexy was associated with decreased CSF hypocretin-1 levels, 22 and our results were in line with their findings. We speculate that a similar relationship between the HLA profile and the CSF hypocretin-1 level could also exist in narcolepsy without cataplexy.
Although detailed HLA analysis including HLA-DQB1*0602 was carried out in only 5 patients in the present study, at least 83.3% of patients with normal hypocretin-1 levels were regarded to be HLA-DQB1*0602 negative. Moreover, REM pathology on the MSLT and the disease onset were significantly different between the low group and the normal group. Taken together with the difference in the profile of both HLA and hypocretin-1, narcolepsy without cataplexy could be a heterogeneous group, and patients who have narcolepsy without cataplexy who also have normal CSF hypocretin-1 levels may have a different pathophysiologic mechanism from that of patients with typical narcolepsy with cataplexy.
In conclusion, some patients who have narcolepsy without cataplexy have low CSF hypocretin-1 levels, and they are more likely to have an early clinical onset, shorter mean REM latency, and positive HLA status. Thus, CSF hypocretin-1 levels may become a useful clue in distinguishing subgroups of patients who have narcolepsy without cataplexy, reflecting different pathophysiologic mechanisms.
